Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026
The source supplies the latest action, but no lifecycle stage.
Latest action (13 Aug 2026): Referred to the House Committee on Energy and Commerce.
What this bill does
This bill, the Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026, would require federal agencies that provide research funding—through grants, contracts, cooperative agreements, or licenses of related patents or regulatory data—to include a "reasonable pricing" requirement in those agreements for any resulting biomedical product or service. Pricing formulas would have to ensure U.S. residents pay no more than the median price charged in Canada and six other large, high-income OECD countries, though the Secretary of Health and Human Services could modify this standard through rulemaking. The Secretary could also issue additional rules to enforce reasonable pricing, using mechanisms such as reducing prices or exclusivity periods when revenues exceed targets, or when prices exceed cost-effectiveness or affordability thresholds. Waivers from these requirements would be allowed only after public notice, comment, and an economic justification.
The bill primarily affects companies and researchers who receive federal funding for developing drugs, vaccines, devices, diagnostics, or similar health technologies, as they would face new pricing obligations and reporting requirements—covering clinical trial costs, federal subsidies, and revenues by location—that HHS would make public. Patients and taxpayers could be affected through potential effects on drug pricing and access.
The bill was introduced on August 13, 2026, by Rep. Valerie Hoyle and referred to the House Committee on Energy and Commerce. It has not yet received a committee vote, floor action, or further consideration.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Timeline
13 Aug 2026
Referred to the House Committee on Energy and Commerce.
Common questions
- What does H.R. 10094 do?
- This bill, the Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026, would require federal agencies that provide research funding—through grants, contracts, cooperative agreements, or licenses of related patents or regulatory data—to include a "reasonable pricing" requirement in those agreements for any resulting biomedical product or service. Pricing formulas would have to ensure U.S. residents pay no more than the median price charged in Canada and six other large, high-income OECD countries, though the Secretary of Health and Human Services could modify this standard through rulemaking. The Secretary could also issue additional rules to enforce reasonable pricing, using mechanisms such as reducing prices or exclusivity periods when revenues exceed targets, or when prices exceed cost-effectiveness or affordability thresholds. Waivers from these requirements would be allowed only after public notice, comment, and an economic justification. The bill primarily affects companies and researchers who receive federal funding for developing drugs, vaccines, devices, diagnostics, or similar health technologies, as they would face new pricing obligations and reporting requirements—covering clinical trial costs, federal subsidies, and revenues by location—that HHS would make public. Patients and taxpayers could be affected through potential effects on drug pricing and access. The bill was introduced on August 13, 2026, by Rep. Valerie Hoyle and referred to the House Committee on Energy and Commerce. It has not yet received a committee vote, floor action, or further consideration.
- Has H.R. 10094 become law?
- The source does not supply a confirmed lifecycle stage for H.R. 10094. Check the latest action and official source below.
- Who sponsored H.R. 10094?
- H.R. 10094 was sponsored by Rep. Hoyle, Val T. [D-OR-4] (D-OR), with 15 cosponsors.
- What's the latest action on H.R. 10094?
- Referred to the House Committee on Energy and Commerce. (13 Aug 2026).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Lower Premiums, Faster Payments Act
340B Rebate Model Delay Act
More bills from Rep. Hoyle, Val T. [D-OR-4]
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.